Benedetto Gregory, Hamp Timothy J, Wesselman Peter J, Richardson Christine
1Department of Biological Sciences, University of North Carolina Charlotte, Charlotte, North Carolina.
2College of Computing and Informatics, University of North Carolina Charlotte, Charlotte, North Carolina.
Nucleic Acid Ther. 2015 Jun;25(3):162-72. doi: 10.1089/nat.2014.0522. Epub 2015 Apr 20.
Ovarian cancer is often diagnosed in late stages with few treatment options and poor long-term prognosis. New clinical tools for early detection of ovarian malignancies will significantly help reduce mortality and improve current long-term survival rates. The objective of this work was to identify ovarian tumor-specific single-stranded DNA aptamers that bind to malignant ovarian tumor cells and internalize with high affinity and specificity. Aptamers can identify unique tumor biomarkers, can aid in early detection and diagnosis of neoplastic disorders, and can be functionalized by conjugation to small molecules. To identify aptamers from random single-stranded DNA pools (60 bases long), we used whole Cell-SELEX (systematic evolution of ligands by exponential enrichment) to enrich and isolate tumor-specific aptamers that bind to tumor-specific receptors in their native state on the cell surface. Next-Generation sequencing identified seven novel aptamers and detailed analyses of three are described. Aptamers bound to, and were internalized by, target Caov-3 cell populations, but not nontarget nonmalignant ovarian epithelial HOSE 6-3 cells or multiple other epithelial tumor cell lines. Furthermore, aptamers showed unique binding affinities with apparent dissociation constants (Kd) measuring in the submicromolar range supporting their physiological relevance and potential use in clinical applications.
卵巢癌通常在晚期才被诊断出来,治疗选择有限,长期预后较差。用于早期检测卵巢恶性肿瘤的新临床工具将显著有助于降低死亡率并提高当前的长期生存率。这项工作的目的是鉴定与恶性卵巢肿瘤细胞结合并以高亲和力和特异性内化的卵巢肿瘤特异性单链DNA适配体。适配体可以识别独特的肿瘤生物标志物,有助于肿瘤性疾病的早期检测和诊断,并且可以通过与小分子偶联进行功能化。为了从随机单链DNA库(60个碱基长)中鉴定适配体,我们使用全细胞SELEX(指数富集配体系统进化)来富集和分离在细胞表面天然状态下与肿瘤特异性受体结合的肿瘤特异性适配体。下一代测序鉴定出七种新型适配体,并描述了其中三种的详细分析。适配体与靶标Caov-3细胞群体结合并被其内化,但不与非靶标非恶性卵巢上皮HOSE 6-3细胞或多种其他上皮肿瘤细胞系结合。此外,适配体显示出独特的结合亲和力,其表观解离常数(Kd)在亚微摩尔范围内,支持它们的生理相关性以及在临床应用中的潜在用途。